Adaptive Biotechnologies reports Q3 EPS (22c), consensus (29c)

Reports Q3 revenue $46.4M, consensus $40.21M.”Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Immune Medicine programs,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “The increased clonoSEQ( Medicare Gapfill rate and the extension of coverage to Mantle Cell Lymphoma underscore clonoSEQ’s value to patients. I look forward to a strong finish to the year and continued progress toward our strategic goals.”